Akili, Inc.
Healthcare · Surgical & Medical Instruments & Apparatus · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | |
|---|---|---|---|
| Revenue | $1.7M | $323,000 | $538,000 |
| Operating income | −$64.5M | −$90.7M | −$2.4M |
| Net income | −$59.5M | −$8.0M | −$2.4M |
| Total assets | $80.4M | $144.6M | $251.2M |
| Total liabilities | $21.9M | $33.9M | $9.7M |
| Equity | $58.5M | $110.7M | $0 |
| EPS (diluted) | $-0.76 | $-0.64 | $-91.88 |
| Shares out. | 78.1M | 78.0M | 10,000 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −3843.0%
- Net margin
- −3545.5%
- Return on equity
- −101.6%
- Return on assets
- −74.0%
- Return on capital (ROCE)
- −95.7%
- Liabilities / assets
- 27.2%
- Debt / equity
- 0.37×
- Book value / share
- $0.75
- Revenue growth (YoY)
- 419.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -9.43distress
- Accruals / assets
- −2.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJul 2, 2024
- Other material eventJun 18, 2024
- Entered a material agreement · Regulation FD disclosureMay 29, 2024
- Results of operationsMay 14, 2024
- Entered a material agreement · Costs from exit or disposal · Other material eventApr 30, 2024
- Delisting / listing-standard notice · Shareholder voteApr 23, 2024
- Results of operationsFeb 29, 2024
- Other material eventFeb 26, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 13, 2024
- SC 13G/AAug 9, 2024
- SC 13G/AAug 5, 2024
- 15-12GJul 12, 2024
- EFFECTJul 9, 2024
- SC 13D/AJul 9, 2024
- 4Jul 8, 2024
- 4Jul 5, 2024
- SC 13D/ASCHEDULE 13D, AMENDMENT NO. 3Jul 5, 2024
- SC 13G/AJul 5, 2024
- 4Jul 5, 2024
- 4PRIMARY DOCUMENTJul 2, 2024
- 4PRIMARY DOCUMENTJul 2, 2024
- 4PRIMARY DOCUMENTJul 2, 2024
- 4PRIMARY DOCUMENTJul 2, 2024